Drug Discovery World

APRIL 13, 2023

The Biology Unveiled track will feature scientific sessions focusing on the hot topic of personalised medicine, along with advances in the uses of CRISPR and vessels-on-a-chip. Sixteen speakers will showcase the latest drug discovery research in this vast topic based on tiny particles. View the Full SLAS Europe 2023 Programme.

In-Vitro 52

In-Vitro Genome Genomics Engineer 52

Pharmaceutical Technology

APRIL 13, 2023

Released on April 12, the report focuses on bluebird bio’s lovotibeglogene autotemcel and Vertex Pharmaceuticals and CRISPR Therapeutics’ exagamglogene autotemcel or exa-cel and their potential use in treating sickle cell disease. If approved, exa-cel would be the first FDA-approved gene therapy based on CRISPR editing.

Gene Therapy 147

Gene Therapy Gene FDA Approval Licensing 147

Drug Discovery World

DECEMBER 21, 2023

In a record year for gene therapy approvals, it isn’t surprising that cell & gene therapy (CGT) has been a hot topic. Other biotechnologies coming to the fore this year were antibody-drug conjugates and CRISPR gene editing. DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development.

Gene Therapy 59

Gene Therapy Gene Antibody FDA Approval 59

Pharmaceutical Technology

APRIL 5, 2023

This includes the first potential approval of a CRISPR-based gene therapy called exa-cel , which is developed by CRISPR Therapeutics and Vertex Pharmaceuticals. But I think we’ve never had more tools than we have now in synthetic biology, genetic engineering, enhanced potency design switches and CRISPR.

Gene Therapy 147

Gene Therapy Gene Engineer Production 147

Pharmaceutical Technology

OCTOBER 5, 2022

In September this year, the company and Scribe Therapeutics entered a strategic partnership to expedite the development of CRISPR-based cell therapies for cancer. Topic sponsors are not involved in the creation of editorial content. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Development 130

Development RNA Gene Therapy Sales 130

pharmaphorum

FEBRUARY 23, 2022

In this context, the 2 nd Annual Gene Therapy Patient Engagement Summit will unite patient advocacy and engagement leaders from gene therapy and gene editing drug developers, patient groups and patients themselves to address the specific challenges of genetic therapy patient engagement, generating actionable insights through detailed case studies (..)

Gene Therapy 52

Gene Therapy Gene Gene Editing Clinical Trials 52

pharmaphorum

MARCH 19, 2021

Protein misfolding has become a hot topic in the biopharma industry, with a clutch of emerging companies targeting the broad range of diseases that feature aberrant proteins.

Protein 103

Protein Gene Editing Drugs Clinical Trials 103

pharmaphorum

NOVEMBER 1, 2022

Further topics to be examined comprise of novel RNA modalities encompassing self-amplifying RNA, saRNA, circular RNA, lnc RNA and many more. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%.

RNA 52

RNA Genetics Gene Editing In-Vitro 52

Drug Discovery World

OCTOBER 13, 2022

The turn-out for the Tech Theatre was rewarding for the DDW team as well as the experts who presented, as the relevance of the topics covered was made clear. This was one of a varied range of keynote presentations covering a diverse range of drug discovery topics. . Presentations . Read more on the programme here.

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

Pharmaceutical Technology

MAY 17, 2023

Scribe Therapeutics has entered a strategic collaboration with Eli Lilly and Company subsidiary Prevail Therapeutics for accelerating in vivo CRISPR-based therapies to target the causes of serious neurological and neuromuscular diseases. Topic sponsors are not involved in the creation of editorial content.

Genetics 130

Genetics Medicine In-Vivo Gene Therapy 130

Pharmaceutical Technology

APRIL 4, 2023

Vertex Pharmaceuticals and CRISPR Therapeutics have completed the rolling submission of biologics licence applications (BLAs) to the US Food and Drug Administration (FDA) for exagamglogene autotemcel (exa-cel) to treat sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

Gene Therapy 246

Gene Therapy Gene Editing In-Vivo Gene 246

Pharma Marketing Network

DECEMBER 21, 2020

conflation of traditional gene therapy and gene editing; the use of “CRISPR” as a synonym, rather than a synecdoche, for gene editing; and confusion between in vivo and ex vivo applications of these technologies). This makes it challenging for them to reconstruct their prior state of mind in which they did not understand the topic. #5.

Genetics 52

Genetics Medicine Gene Therapy Marketing 52

pharmaphorum

APRIL 20, 2022

The potential of CRISPR technology has been a hot topic in the industry ever since it was first developed, but as trials progress further into the clinic, what therapeutic areas could be set to benefit? Ben Hargreaves takes a look at why oncology could be one of the major beneficiaries of a growing pipeline of CRISPR therapeutics.

Gene Editing 52

Gene Editing DNA Gene Genetics 52

Drug Discovery World

DECEMBER 14, 2023

It is home to companies like ILC Therapeutics, founded by an Emeritus Professor of Immunology from the University of Strathclyde, Glasgow) and currently developing a topical treatment for moderate/severe psoriasis; and The Antibody Company, a specialist contract manufacturing company with expertise in the production of monoclonal antibodies.

Drugs 75

Drugs Life Science Research Scientist 75

XTalks

MARCH 25, 2021

To complement its leading webinar, editorial and video content, the podcast will explore the latest news and hot topics in the pharmaceutical, biotechnology and medical device spaces. Fresh Conversations About Life Science Topics. Xtalks is proud to announce the launch of the Xtalks Life Science podcast.

Life Science 105

Life Science HR Clinical Trials Clinical Trials 105

XTalks

SEPTEMBER 12, 2023

Our Podcast Delivers Diverse Perspectives on Trending Topics: At Xtalks, we believe in fostering meaningful discussions. Our podcast offers diverse perspectives on trending topics, allowing you to stay informed about the latest industry issues and the developments.

Life Science 105

Life Science Branding Clinical Trials Clinical Trials 105

Pharmaceutical Technology

JANUARY 10, 2023

AskBio CEO Sheila Mikhail said: “The collaboration pairs AskBio’s expertise in synthetic DNA and CRISPR applications with ReCode’s novel SORT LNP delivery technology to potentially discover new genetic medicines. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper.

Gene Editing 130

Gene Editing Gene Gene Therapy Genetics 130

Drug Discovery World

OCTOBER 16, 2023

James Barder, CEO of Futura says: “The UK is a hotspot for life science innovation and an ideal home for Futura Medical, which has developed Eroxon, a breakthrough topical gel formulation for erectile dysfunction – now sold in the UK and other international markets.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

XTalks

DECEMBER 22, 2021

Here is a look at some life science trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022. The gene-editing tool CRISPR edits DNA using specialized strands of guide RNA and endogenous cellular mechanisms of RNA interference.

Life Science 98

Life Science RNA Vaccination Vaccine 98

XTalks

FEBRUARY 11, 2021

After several such Nobel Prize snubs for female scientists, 2020 saw the Nobel Prize in Chemistry go to a female scientist duo for the first time for their revolutionary discovery of the CRISPR-Cas9 gene editing system. Jennifer Doudna and Emmanuelle Charpentier Pioneer with CRISPR. Emmanuelle Charpentier.

Genetics 119

Genetics DNA Genome Genomics 119

Drug Discovery World

OCTOBER 12, 2023

Such approaches may include cellular technologies for drug discovery, such as a 3D screening model, a topic which will be discussed at Drug Discovery 2023. When it comes to the technologies driving drug discovery, she thinks that the ability to specifically edit regions of the genome using CRISPR/Cas9 is particularly revolutionary.

Drugs 59

Drugs Life Science Genome Genomics 59

Pharma Marketing Network

JANUARY 20, 2021

Here, we provide some insights on 3 key topics based on panel discussions with industry leaders at this year’s event. #1. In other areas of the industry (such as cell and genetic medicine development) progress continued at an impressively brisk pace despite the pandemic.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52